Shots:

• The approval is based on the CodeBreaK 100 trial evaluating the efficacy & tolerability of Lumakras (960mg- qd) in 124 patients with KRAS G12C mutation-positive NSCLC whose disease had progressed after prior treatment with immunotherapy or CT
• Results: ORR (36%); DCR (81%); mDoR (10 mos.); durable response with a positive benefit-risk profile- 9% showed permanent discontinuation due to AEs
• The company is conducting biomarker testing & a patient support program for NSCLC. The therapy is also being studied in multiple other solid tumors

  Ref: PRNewswire | Image: BioSpace